Aslan E, Körber A, Grabbe S, Dissemond J
Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Essen, Essen, Deutschland.
Hautarzt. 2007 Aug;58(8):684-8. doi: 10.1007/s00105-006-1282-9.
Necrobiosis lipoidica is an inflammatory granulomatous skin disease of unknown etiology which is associated with diabetes mellitus in about 60% of the patients. In 15-35% of the affected patients painful ulcerations may occur after minimal trauma which can be extremely refractory to therapy. Because of the unknown pathomechanisms, current therapeutic options are limited. We report on a 68-year-old patient with an 18 year history of ulcerated necrobiosis lipoidica non diabeticorum of both lower limbs, which responded to systemic cyclosporine A. Based on this case, we discuss the role of cyclosporine A in patients with necrobiosis lipoidica in the context of the disease etiology.
脂性渐进性坏死是一种病因不明的炎症性肉芽肿性皮肤病,约60%的患者与糖尿病有关。在15%-35%的受累患者中,轻微创伤后可能会出现疼痛性溃疡,治疗极为棘手。由于发病机制不明,目前的治疗选择有限。我们报告了一名68岁的患者,双下肢患有溃疡性非糖尿病性脂性渐进性坏死18年,对全身性环孢素A有反应。基于此病例,我们在疾病病因的背景下讨论环孢素A在脂性渐进性坏死患者中的作用。